A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Recruiting now · Phase 1/Phase 2
Conditions studied: NSCLC
In brief
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
Key facts
- Study ID
- NCT04077099
- Run by
- Regeneron Pharmaceuticals
- People needed
- 231
- Starts
- 2020-01-07
- Expected to finish
- 2032-04-22
- Last updated by the study team
- 2026-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- National Cancer Center — Gyeonggi-do, Gyeonggi-do, South Korea (enrolling)
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea (enrolling)
- The Catholic University Of Korea St. Vincent's Hospital — Suwon, Gyeonggi-do, South Korea (enrolling)
- Ajou University Hospital — Suwon, Gyeonggi-do, South Korea (enrolling)
- Haeundae Paik Hospital — Pusan, Gyeongsangnam-do, South Korea (enrolling)
- Chonnam National University Hwasun Hospital — Hwasun, Jeollanam-do, South Korea (enrolling)
- Gachon University Gil Medical Center — Incheon, Namdong-gu, South Korea (enrolling)
- Chungbuk National University Hospital — Cheongju-si, North Chungcheong, South Korea (enrolling)
- Pusan National University Hospital — Busan, South Korea (enrolling)
- Severance Hospital Yonsei University Health System — Seoul, South Korea (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Moffitt Cancer Center - McKinley Drive — Tampa, Florida, United States (enrolling)
- Boramae Medical Center — Seoul, South Korea (enrolling)
- Korea University Guro Hospital — Seoul, South Korea (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou — Rennes, Bretange, France
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- Centre Francois Baclesse (CFB) — Caen, Normandy, France
- Centre Hospitalier Universitaire de Grenoble — Grenoble, France
- Centre Hospitalier Regional Universitaire (CHRU) Montpellier Arnaud de Villeneuve — Montpellier, France
- Seol St. Mary's Hospital — Seoul, South Korea
- Institut Bergonie — Bordeaux, New Aquitaine, France
- University of California Irvine Medical Center - Bldg 56, RT81, Rm 241 — Orange, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.